≥99% PURITY GUARANTEED•THIRD-PARTY TESTED•SAME-DAY SHIPPING USA•FREE SHIPPING $200+•
Menu
≥99% Purity
Same-Day Ship
COA Included
GLP2-T - 5 mg
Popular Peptides

GLP2-T

Dual GIP/GLP-1 receptor agonist research peptide.

$50.00
99.67% Purity Verified

Third-Party Tested by Verum Analytics

Batch: BIL-BATCH-01-2602Mar 2, 2026
+99% Purity
Third-Party Tested
COA Available
34 sold in the last 24 hours
Order in 0h 0min for same-day shipping
Buy More, Save More
QuantityPrice
Add 2 more for 15% off
$50.00
Albert - Chief Researcher

Albert's Verdict

GLP2-T's intestinal trophic effects are highly localized — the receptor distribution in the gut mucosa is what makes it interesting as a standalone metabolic research target, separate from the GLP-1 pathway entirely.

View COA

✓ In stock - Ships same day

Arrives as lyophilized (powder) form

Shipped freeze-dried for maximum stability and shelf life. See laboratory preparation guide for handling instructions.

Secure Checkout256-bit SSL
99%+ PurityThird-Party Verified
Same-Day ShippingOrder by 2PM EST
Satisfaction Guarantee

Product Description

GLP2-T is a dual-action GIP/GLP-1 receptor agonist research peptide investigated in laboratory research models. It is studied for activation of both the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor signaling pathways.

Molecular Profile:

  • Classification: Dual GIP/GLP-1 Receptor Agonist
  • Targets: GIPR + GLP-1R
  • Mechanism: Dual incretin receptor activation

Research Applications:

  • Dual incretin-pathway research models
  • Glycemic-pathway research compared with mono-agonist research
  • Adipose-tissue cellular research models
  • Lipid-metabolism and hepatic cellular research models
  • Beta-cell function research models
  • Cardiovascular pathway research models

Quality Standards:

  • Purity: ≥99% verified by HPLC
  • Third-party tested with COA included

For laboratory handling instructions, refer to the Preparation Guide. Published trial dosing information from external literature is provided separately on the Literature References page and is not product-use guidance.

FOR RESEARCH USE ONLY. Not for human or animal consumption.

Technical Specifications

Molecular Formula
C225H348N48O68
Molecular Weight
4813.45 g/mol
Sequence
Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Ala-Met-Asp-Lys(palmitoyl-γGlu-AEEA-AEEA)-Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser

Frequently Researched Together

Commonly studied alongside in laboratory settings

Bundle total (3 items):$142.00

Research FAQ — GLP2-T

Frequently asked questions about this compound for laboratory researchers.

What is Tirzepatide / GLP-2-T?+
Tirzepatide is a dual-agonist research peptide that activates GLP-1 and GIP receptors. Published clinical-trial data describe glycemic and body-composition outcomes in research populations under controlled conditions.
Cited: PMID 34324827, PMID 35707975
How does Tirzepatide differ from Semaglutide in published research?+
SURPASS-2 (NEJM, 2021) compared Tirzepatide with Semaglutide head-to-head in research subjects with type 2 diabetes. The published data report differentiated effects on A1C and body-weight endpoints.
Cited: PMID 34324827
What dosing schedule is reported in Tirzepatide research?+
Published trial protocols administer Tirzepatide once weekly via subcutaneous injection at doses of 2.5–15 mg. Researchers should reference the cited publications and their IRB-approved protocols.
Cited: PMID 34324827, PMID 35707975
How is Tirzepatide stored?+
Lyophilized Tirzepatide is stored at −20 °C protected from light. Reconstituted solution is held at 2–8 °C, typically used within 28 days. See product COA for batch-specific details.

Published research references

Peer-reviewed literature relevant to GLP2-T research. Linked PubMed IDs open the original source.

  1. [1]Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med (2022) · PMID 35707975
  2. [2]Tirzepatide versus Semaglutide once weekly in patients with type 2 diabetes (SURPASS-2) — N Engl J Med (2021) · PMID 34324827
  3. [3]Tirzepatide for type 2 diabetes: SURPASS-1 trial — Lancet (2021) · PMID 34108239
BL
Reviewed by the BioInfinity Research Team
Content reviewed by our research and quality team — biochemistry-degreed reviewers working alongside our analytical lab partner (Janoshik Analytical). Every product page is cross-checked against the cited peer-reviewed literature and the current batch's third-party COA.
For laboratory research use only. Not for human or veterinary use. Content is informational and does not constitute medical advice.

Learn More About This Peptide

GLP2-T Research Summary →Browse All Peptide Research →Research Guides & Protocols

Research Use Only: This product is intended for laboratory research purposes only. Not for human consumption.